AstraZeneca Singapore

AstraZeneca to Establish $1.5 Billion ADCs Facility in Singapore

Exciting news! AstraZeneca plans a groundbreaking investment in Singapore to revolutionize cancer drug manufacturing.

AstraZeneca is set to make a significant mark in Singapore with its plan to build a $1.5 billion manufacturing facility dedicated to the production of antibody drug conjugates (ADCs) and targeted cancer therapies. This state-of-the-art facility will be the first of its kind for AstraZeneca, offering full manufacturing processing for ADCs, showcasing the company's commitment to cutting-edge innovation in the pharmaceutical industry.

Supported by Singapore's Economic Development Board, this manufacturing plant will be a game-changer, incorporating all steps of the production process at a commercial scale. Notably, the facility is designed to be 'zero carbon,' aligning with AstraZeneca's sustainable practices and environmental responsibility.

With the global spotlight on AstraZeneca's $1.5 billion investment, Singapore's pharmaceutical landscape is poised for a transformation, with the potential to boost the country's position as a hub for advanced healthcare technologies and cancer treatment innovations.

As AstraZeneca gears up to enhance the global supply of its ADC portfolio, this strategic move not only signifies a milestone in pharmaceutical manufacturing but also underscores the company's dedication to advancing cancer treatment and patient care.